
News|Articles|December 1, 2006
FDA Actions in Brief (December 2006)
Imatinib (Gleevec, Novartis) was approved for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia, certain forms of myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Top 5 stories from Formulary Watch in 2025
2
Top 5 articles about drug and healthcare costs in 2025
3
What NCCN’s next CMO sees ahead for cancer guidelines, access and innovation
4
A look back at 2025’s sunscreen controversy and confusion
5




















































